STAT | Reporting from the frontiers of health and medicine Follow STAT+: The limits of FDA flexibility are tested as a controversial Biohaven drug decision nears An upcoming decision on a rare disease drug from Biohaven Pharmaceuticals should shed light on regulatory flexibility under the current FDA leadership. https://www.statnews.com/2025/10/09/biohaven-pharmaceuticals-spinocerebellar-ataxia-troriluzole-fda-flexibility/ statnews.com
